



## Berkshire West Area Prescribing Committee Policy Statement

<b>Drug Name</b>	Lurasidone (Latuda®)
<b>Indication under review</b>	The treatment of schizophrenia in adults aged 18 years and over
<b>Policy No:</b>	APC 143
<b>Date of Issue:</b>	March 2017
<b>Review Date:</b>	March 2020
<b>Policy Statement:</b> Lurasidone (Latuda®) is approved for use as a third line antipsychotic for those patients; who have experienced weight gain or prolactin elevation, for those who cannot tolerate aripiprazole (which is the preferred option for patients who have experienced; weight gain, prolactin elevation, cardiovascular risk factors or renal impairment)	
<b>Traffic Light Status:</b>	<b>Amber (see restrictions above)</b>
<b>Key Points considered:</b> <ul style="list-style-type: none"> <li>• Lurasidone (Latuda®) can be considered as a third line treatment for patients with schizophrenia who have tried at least two antipsychotics but were unable to continue treatment due to unacceptable side-effects. Treatment must have included aripiprazole.</li> <li>• Treatment will be initiated by a Consultant Psychiatrist until the symptoms are effectively controlled.</li> <li>• The APC discussed results of the internal 6 month validation at BHFT and Dr Parry was available to discuss the outcomes.</li> <li>• The committee were satisfied that there are aspects of treatment that are favourable. Aripiprazole would normally be used when side-effects such as weight gain or prolactin elevation are troublesome but can be agitating in some patients.</li> </ul>	
<b>Date taken to APC:</b>	1 <sup>st</sup> March 2017
<b>Date Ratified by GPMOC on Behalf of the Board:</b>	15 <sup>th</sup> March 2017

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

<b>Brown</b>	<b>Green</b>	<b>Amber</b>	<b>Red</b>
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only